首页> 美国卫生研究院文献>Neuroscience Journal >Impact of Blood Vessel Quantity and Vascular Expression of CD133 and ICAM-1 on Survival of Glioblastoma Patients
【2h】

Impact of Blood Vessel Quantity and Vascular Expression of CD133 and ICAM-1 on Survival of Glioblastoma Patients

机译:血管数量和CD133和ICAM-1的血管表达对胶质母细胞瘤患者生存的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Glioblastoma (GB) is the most angiogenic tumor. Nevertheless, antiangiogenic therapy has not shown significant clinical efficacy. The aim of this study was to assess blood vessel characteristics on survival of GB patients. Surgically excised GB tissues were histologically examined for overall proportion of glomeruloid microvascular proliferation (MP) and the total number of blood vessels. Also, immunohistochemical vascular staining intensities of CD133 and ICAM-1 were determined. Vessel parameters were correlated with patients' overall survival. The survival time depended on the number of blood vessels (p = 0.03) but not on the proportion of MP. Median survival times for patients with low (<median) and high (≥median) number of blood vessels were 9.0 months (95% CI: 7.5–10.5) and 12.0 months (95% CI: 9.3–14.7). Also, median survival times for patients with low (<median) and high (≥median) vascular expression level of CD133 were 9.0 months (95% CI: 8.0–10.1) and 12.0 months (95% CI: 10.3–13.7). In contrast, the staining intensity of vascular ICAM-1 did not affect survival. In multivariate analysis, the number of blood vessels emerged as an independent predictor for longer overall survival (HR: 2.4, 95% CI: 1.2–5.0, p = 0.02). For success in antiangiogenic therapy, better understanding about tumor vasculature biology is needed.
机译:胶质母细胞瘤(GB)是最血管生成的肿瘤。然而,抗血管生成疗法尚未显示出显着的临床疗效。这项研究的目的是评估GB患者生存的血管特征。手术切除的GB组织在组织学上检查肾小球微血管增殖(MP)的总比例和血管总数。另外,测定了CD133和ICAM-1的免疫组织化学血管染色强度。血管参数与患者的总体生存率相关。存活时间取决于血管数量(p = 0.03),而不取决于MP的比例。低(<中位数)和高(≥中位数)血管患者的中位生存时间分别为9.0个月(95%CI:7.5-10.5)和12.0个月(95%CI:9.3-14.7)。同样,低(<中位数)和高(≥中位数)CD133血管表达水平患者的中位生存时间分别为9.0个月(95%CI:8.0-10.1)和12.0个月(95%CI:10.3-13.7)。相反,血管ICAM-1的染色强度不影响存活。在多变量分析中,血管数目是总体生存期更长的独立预测因子(HR:2.4,95%CI:1.2–5.0,p = 0.02)。为了成功地进行抗血管生成治疗,需要对肿瘤脉管系统生物学有更好的了解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号